CompletedNCT01412060
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
Medication studyAges 18–60Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Little Rock and 72 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 27, 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 765
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, India, Romania, ...
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01412060
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · Cerritos, United States · Costa Mesa, United States
54 more locations
- Culver City, United States
- Long Beach, United States
- Oceanside, United States
- Orange, United States
- Paramount, United States
- San Diego, United States
- Washington D.C., United States
- Leesburg, United States
- Atlanta, United States
- Chicago, United States
- Baltimore, United States
- Rockville, United States
- Flowood, United States
- Creve Coeur, United States
- St Louis, United States
- Cedarhurst, United States
- Dayton, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Vijayawada, India
- Ahmedabad, India
- Mangalore, India
- Manipal, India
- Aurangabad, India
- Kalyān, India
- Nashik, India
- Jaipur, India
- Madurai, India
- Kanpur, India
- Lucknow, India
- Varanasi, India
- Bucharest, Romania
- Campulung Muscel, Romania
- Constanța, Romania
- Focşani, Romania
- Iași, Romania
- Targoviste, Romania
- Bratislava, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Trnava, Slovakia
- Kerch, Ukraine
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Vinnytsia, Ukraine
Questions about this study
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo and Cariprazine.
Who was this study for?
Listed age limits: 18 years to 60 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia